H-CYTE Completes Acquisition of SkinDisc™ Regenerative Tissue Kit from Scio

Wound Healing and Limb Salvage Technology Added to Growing Asset Portfolio

Company’s Second Completed Transaction in Four Months TAMPA, Fla., Dec. 29, 2022 (GLOBE NEWSWIRE) — H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, announced today that the Company completed its acquisition of SkinDisc™.

H-CYTE, Inc. continues to expand its asset portfolio with the recent acquisition of SkinDisc™, a regenerative tissue kit designed for wound healing and limb salvage technology. This marks the company’s second completed transaction in the past four months, further solidifying its position in the medical biosciences industry.

The addition of SkinDisc™ to H-CYTE’s portfolio will not only diversify its assets but also enhance its capabilities in providing innovative solutions for patients in need of advanced wound healing treatments. Early clinical outcomes of SkinDisc™ have shown promising results, reinforcing the company’s commitment to delivering cutting-edge regenerative medicine technologies.

With this strategic acquisition, H-CYTE, Inc. is poised to drive significant growth and make a positive impact on the healthcare industry. The company’s dedication to advancing medical biosciences reflects its mission to improve patient outcomes and contribute to the advancement of regenerative medicine.

Implications for Individuals

Individuals who require advanced wound healing and limb salvage treatments may benefit from H-CYTE’s acquisition of SkinDisc™. This innovative technology has the potential to improve patient outcomes and provide new solutions for individuals with complex medical needs.

Impact on the World

H-CYTE’s acquisition of SkinDisc™ represents a major advancement in regenerative medicine technology. By expanding its asset portfolio and investing in cutting-edge treatments, the company is contributing to the global effort to enhance healthcare solutions and improve patient well-being on a worldwide scale.

Conclusion

In conclusion, H-CYTE, Inc.’s acquisition of SkinDisc™ demonstrates the company’s commitment to innovation and growth in the medical biosciences industry. With this strategic move, H-CYTE is poised to make a significant impact on patient care and drive advancements in regenerative medicine technology. This acquisition marks a milestone in the company’s journey towards improving healthcare outcomes and contributing to the global advancement of medical solutions.